Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Virtual Reality
Interventions: Pain Rehabilitation Virtual Reality (PRVR), Standard Physiotherapy Rehabilitation (SPR); Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Menlo Park, California • Palo Alto, California

Conditions: Diabetic Macular Edema
Interventions: RO7446603, Aflibercept, Faricimab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 70
States / cities: Phoenix, Arizona • Springdale, Arkansas • Campbell, California + 60 more

Conditions: Respiratory Distress Syndrome, Hyperoxia, Prematurity
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: Up to 3 Months
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Gout
Interventions: ABP-671, Allopurinol; Drug
Lead sponsor: Atom Therapeutics Co., Ltd; Industry
Eligibility: 19 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 33
States / cities: Tempe, Arizona • Tucson, Arizona • Anaheim, California + 24 more

Conditions: Non Hodgkin Lymphoma, Heart; Functional Disturbance, Hodgkin Lymphoma, Quality of Life, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions: Exercise with Trainerize application, Cardiopulmonary exercise testing, MRI scan, Quality of Life Questionnaires, Cognitive and Brain Function Questionnaires, Blood draws; Other · Diagnostic Test · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 85 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Winston-Salem, North Carolina • Richmond, Virginia

Conditions: Solid Tumor
Interventions: PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more

Conditions: Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
Interventions: HM15136, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: GM1 Gangliosidosis, GM1 Gangliosidosis, Type I, GM1 Gangliosidosis, Type 2, Beta-Galactosidase-1 (GLB1) Deficiency
Interventions: PBGM01; Biological
Lead sponsor: Gemma Biotherapeutics; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Oakland, California • Minneapolis, Minnesota • New Brunswick, New Jersey + 1 more

Conditions: Major Depressive Disorder
Interventions: Repetitive transcranial magnetic stimulation (rTMS); Device
Lead sponsor: Paul E. Croarkin; Other
Eligibility: 12 Years to 21 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Rochester, Minnesota • Charleston, South Carolina

Conditions: B-cell Non-Hodgkins Lymphoma (B-NHL)
Interventions: Odronextamab, REGN5837; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 9
States / cities: Duarte, California • Santa Monica, California • Louisville, Kentucky + 4 more

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Hepatitis C
Interventions: INX-08189, Placebo matching with INX-08189, Pegylated interferon alfa-2a, Ribavirin, Daclatasvir; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Anaheim, California • La Jolla, California • San Francisco, California + 3 more

Conditions: Cytopenia
Interventions: Emapalumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease
Interventions: ACE-083; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 19
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 16 more

Conditions: Advanced Solid Tumors
Interventions: EIK1004-001 (IMP1707-001); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more

Conditions: Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Graft vs. Host Disease (GvHD)
Interventions: Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Gainesville, Florida + 8 more

Conditions: Healthy
Interventions: Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lymphomas, B-cell Lymphomas
Interventions: JV-213, Leukapheresis; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Enfortumab vedotin; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Acute Myeloid Leukemia (AML), Cancer
Interventions: Venetoclax, Azacitidine, Best Supportive Care (BSC); Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 43
States / cities: Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
Interventions: NMP; Device
Lead sponsor: Red Rock Regeneration Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Shreveport, Louisiana • Salt Lake City, Utah

Conditions: Advanced Solid Tumors
Interventions: DT-7012, Immune checkpoint inhibitor; Drug
Lead sponsor: Domain Therapeutics Australia Pty Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Healthy Volunteers
Interventions: KarXT, Midazolam, Fexofenadine, Digoxin; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor
Interventions: NTX-1088, Pembrolizumab; Drug
Lead sponsor: Nectin Therapeutics Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Duarte, California • New Orleans, Louisiana • Houston, Texas

Search by objective public record fields.

Pain Rehabilitation Virtual Reality (PRVR): Innovations to Enhance Mobility in the Presence of Pain

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

Clinical Evaluation of a Closed Loop Oxygen Controller for Neonatal Respiratory Care

Extension Study of ABP-671 in Participants With Gout

Improving Exercise Capacity With a Tailored Physical Activity Intervention

PF-07284892 in Participants With Advanced Solid Tumors

Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

A Safety, Tolerability, PD and PK Study in Healthy Adults

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

INDUCE: A Prospective 2-Year Spine Registry

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab